This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

Stocks to Watch: Barnes & Noble, Gen-Probe (Update 1)

Stocks in this article: NYXHUMAPCWCRXWPIMSFTBKS

Updated with information about Barnes & Noble's deal with Microsoft, Hologic's acquisition of Gen-Probe.

NEW YORK -- Microsoft (MSFT) will make a $300 million investment for a 17.6% stake in a new Barnes & Noble (BKS) subsidiary that will bring together the bookseller's digital and college businesses.

The partnership includes a NOOK application for Windows 8, Barnes & Noble and Microsoft said.

Shares of Barnes & Noble soared 72.08% in premarket trading Monday to $23.54. The stock has fallen 5.52% year to date.

Microsoft shares ticked up 21 cents, or 0.66%, in premarket trading to $32.19. The stock has risen 23.19% year to date.


Hologic (HOLX) agreed to acquire Gen-Probe (GPRO) for $82.75 a share in a cash, or about $3.7 billion..

Shares of Gen-Probe rose 19.33% in premarket trading Monday to $82. The stock has risen 16.23% year to date.

Hologic shares increased 4.8% in premarket trading to $22.25. The stock has gained 21.25% year to date.


NYSE Euronext (NYX) said first-quarter adjusted earnings declined 32%.

The exchange saw a slowdown in trading, particularly in its derivatives trading unit, and was hit by costs associated with its failed merger with Germany's Deutsche Boerse.

Adjusted profit in the quarter was 47 cents a share; analysts were looking for 48 cents.


Humana (HUM), the health care company, reported first-quarter earnings Monday of $248 million, or $1.49 a share, down from year-earlier earnings of $315 million, or $1.86 a share.

First-quarter earnings included a gain of 3 cents a share from previous medical claim reserves; year-earlier earnings included a gain of 31 cents a share.

Humana was expected by analysts to report first-quarter earnings of $1.52 a share.

Humana raised its full-year 2012 guidance to between $7.55 a share and $7.75 a share from a previous range of between $7.50 a share and $7.70 a share. Analysts were calling for earnings of $7.99 a share.

Shares of Humana fell 4.35% in premarket trading Monday to $84. The stock has risen 0.24% year to date.

Apple's Doomed? More Than One Person Thinks So


Watson Pharmaceuticals (WPI) reported non-GAAP first-quarter earnings Monday of $208.8 million, or $1.64 a share, up from year-earlier earnings of $111.9 million, 89 cents.

Analysts were expecting first-quarter profit of $1.60 a share on revenue of $1.48 billion.

Shares of Watson Pharmaceuticals were flat in premarket trading on Monday. The stock has risen 26.22% year to date.

Watson Pharmaceuticals last week agreed to buy competitor Actavis for $5.6 billion.

Sterling CEO: Small Businesses Fueling Loan Growth


Warner Chilcott (WCRX), the drugmaker, is weighing options including a possible sale after receiving interest from strategic and private-equity buyers, according to people with knowledge of the matter, Bloomberg reported.

Shares of Warner Chilcott gained 15.86% in premarket trading Monday to $21.77.


Pall (PLL) agreed to sell certain blood collection assets to Haemonetics (HAE) for about $550 million.

Haemonetics, the blood component collection device company, reported on Sunday fourth-quarter earnings of $17.8 million, or 69 cents a share, down from year-earlier earnings of $21 million, or 81 cents.


Energy company Anadarko Petroleum (APC) is expected by Wall Street analysts to post first-quarter profit of 83 cents a share on revenue of $3.42 billion.

Anadarko reports after the markets close Monday.

10 Ways to Buy a Great Summer at Home


-- Written by Joseph Woelfel



>To contact the writer of this article, click here: Joseph Woelfel

>To submit a news tip, send an email to: tips@thestreet.com.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,810.06 +91.06 0.51%
S&P 500 2,063.50 +10.75 0.52%
NASDAQ 4,712.97 +11.1030 0.24%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs